CytoDyn Inc. CYDY
OTC PK
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.02% | 24.28% | 9.10% | -21.71% | 6.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.00% | 34.15% | 57.46% | 37.60% | 94.07% |
| Operating Income | -33.00% | -34.15% | -57.46% | -37.60% | -94.07% |
| Income Before Tax | -259.86% | -65.58% | 1.43% | -374.14% | -128.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -259.86% | -65.58% | 1.43% | -374.14% | -128.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -259.86% | -65.58% | 1.43% | -374.14% | -128.81% |
| EBIT | -33.00% | -34.15% | -57.46% | -37.60% | -94.07% |
| EBITDA | -32.73% | -34.18% | -57.55% | -37.62% | -94.30% |
| EPS Basic | -212.77% | -47.06% | 4.76% | -333.33% | -128.31% |
| Normalized Basic EPS | -75.00% | -10.00% | -61.54% | -20.00% | -12.00% |
| EPS Diluted | -212.77% | 2.60% | 4.76% | -376.19% | -129.38% |
| Normalized Diluted EPS | -75.00% | -10.00% | -61.54% | -20.00% | -16.67% |
| Average Basic Shares Outstanding | 10.35% | 10.44% | 3.82% | 3.24% | 10.35% |
| Average Diluted Shares Outstanding | 10.35% | 10.44% | 3.82% | 3.24% | 4.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |